Open AccessTrabectedin in the treatment of soft tissue sarcomas: up to date data
Author(s) -
А. А. Феденко,
A. A. Tararykova
Publication year - 2021
Publication title -
sarkomy kostej, mâgkih tkanej i opuholi koži
Language(s) - English
Resource type - Journals
eISSN - 2782-3687
pISSN - 2219-4614
DOI - 10.17650/2782-3687-2021-13-3-16-27
Subject(s) - trabectedin , soft tissue , medicine , soft tissue sarcoma , chemotherapy , sarcoma , oncology , pathology , surgery
Soft tissue sarcomas are a rare heterogeneous group of malignant tumors with mesenchymal nature. Soft tissue sarcomas accounts for less than 1 % of all cancers. Low efficiency of chemotherapy for soft tissue sarcomas, especially in advanced disease, is a burning issue. Trabectedin is one of the active agents approved for the treatment of advanced soft tissue sarcomas after the failure of standard chemotherapy. The article provides a literature review of the latest world-wide data of the effectiveness and role of trabectedin in the modern approach of soft tissue sarcomas treatment.